Follow the GenMark Diagnostics, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 11 February 2016 (Cession). Among the most active insiders: Chakravarty Ingo. The full history is free.
20
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate GenMark Diagnostics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental score
Ranked 25,785 of 28,896 companies
22.7
score / 100
Value
23
Quality
22
FCF yld-4.0%
Earn yld-5.0%
EV/EBITDA·
ROE-40%
Gross mgn40%
Net mgn-77%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
GenMark Diagnostics, Inc. is a company focused on the development of molecular diagnostic tests. It specializes in providing solutions for the rapid diagnosis of infections and diseases.